The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

BACKGROUND Nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors may attenuate the efficacy of antihypertensive agents in high-risk patients. Therefore, we conducted a double-blind, randomized trial to evaluate the effects of celecoxib, rofecoxib, and naproxen on 24-hour blood pressure (BP) in patients with type 2 diabetes, hypertension, and osteoarthritis. METHODS Patients were randomly assigned to treatment with 200 mg of celecoxib once daily (n = 136), 25 mg of rofecoxib once daily (n = 138), or 500 mg of naproxen twice daily (n = 130) for 12 weeks. Twenty-four-hour ambulatory BP monitoring and validated arthritis efficacy assessments were conducted at randomization and at weeks 6 and 12 of treatment. The primary end point was the mean change from baseline in average 24-hour systolic BP at week 6. RESULTS Reductions in osteoarthritis symptoms, including pain, mobility, and stiffness, were similar in all treatment groups. The mean +/- SE 24-hour systolic BP following 6 weeks of therapy was increased significantly by rofecoxib (from 130.3 +/- 1.2 to 134.5 +/- 1.4 mm Hg; P < .001) but not by celecoxib (132.0 +/- 1.3 to 131.9 +/- 1.3 mm Hg; P = .54) or naproxen (133.7 +/- 1.5 to 133.0 +/- 1.4 mm Hg; P = .74). The BP difference between rofecoxib and celecoxib was 3.78 mm Hg (95% confidence interval, 1.18-6.38; P = .005); between rofecoxib and naproxen, 3.85 mm Hg (95% confidence interval, 1.15-6.55; P = .005). The proportion of patients with controlled hypertension at baseline who developed ambulatory hypertension by week 6 (24-hour systolic BP>135 mm Hg) was significantly greater with rofecoxib (30%) than with celecoxib (16%) (P = .05) but not significantly greater than with naproxen (19%). CONCLUSIONS At equally effective doses for osteoarthritis management, treatment with rofecoxib but not celecoxib or naproxen induced a significant increase in 24-hour systolic BP. However, destabilization of hypertension control occurred to some extent in all 3 treatment groups; this phenomenon was seen more often in patients treated with rofecoxib than with the other therapies.

[1]  F. Mckenna,et al.  Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. , 2003, Arthritis and rheumatism.

[2]  T. Kamarck,et al.  Psychosocial mediators of racial differences in nighttime blood pressure dipping among normotensive adults. , 1999, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[3]  G Block,et al.  A data-based approach to diet questionnaire design and testing. , 1986, American journal of epidemiology.

[4]  Jm Jakicic,et al.  Differences in resting energy expenditure in African-American vs Caucasian overweight females , 1998, International Journal of Obesity.

[5]  Gurkirpal Singh,et al.  Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. , 2002, The American journal of managed care.

[6]  T. Schnitzer,et al.  Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. , 2002, JAMA.

[7]  W. White.  Ambulatory blood-pressure monitoring in clinical practice. , 2003, The New England journal of medicine.

[8]  M. Hebl,et al.  The Stigma of Obesity in Women: The Difference is Black and White , 1998 .

[9]  N. Fulop,et al.  Background information. , 1992, The Health service journal.

[10]  Francis J. Keefe,et al.  The Management of Persistent Pain in Older Persons , 2002 .

[11]  K. Matthews,et al.  Chronic stress burden, discrimination, and subclinical carotid artery disease in African American and Caucasian women. , 2003, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[12]  David R. Williams,et al.  Measuring social class in US public health research: concepts, methodologies, and guidelines. , 1997, Annual review of public health.

[13]  W. White,et al.  Long‐term reproducibility of ambulatory blood pressure , 1994, Journal of hypertension.

[14]  J. Speakman.  Obesity: the integrated roles of environment and genetics. , 2004, The Journal of nutrition.

[15]  T. Joiner,et al.  Body image dissatisfaction and disordered eating in black and white women. , 2003, The International journal of eating disorders.

[16]  R. Moskowitz,et al.  Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. , 1986, Arthritis and rheumatism.

[17]  T D Cooke,et al.  The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. , 1991, Arthritis and rheumatism.

[18]  C. Bulpitt,et al.  Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .

[19]  B. Davis,et al.  Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. , 1996, JAMA.

[20]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[21]  W. White,et al.  Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. , 2002, The American journal of cardiology.

[22]  B E Ainsworth,et al.  Physical activity patterns in a diverse population of women. , 1999, Preventive medicine.

[23]  Gianfranco Parati,et al.  Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. , 1999 .

[24]  A. Whelton,et al.  Cyclooxygenase-2–Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients , 2001, American journal of therapeutics.

[25]  N. Bellamy,et al.  Validation study of WOMAC : a health status instrument for measuring clinically-important patient-relevant outcomes following total hip or knee arthroplasty in osteoarthritis , 1988 .

[26]  A. Persons.  The management of persistent pain in older persons. , 2002, Journal of the American Geriatrics Society.

[27]  David Morganstein,et al.  SWAN: A Multicenter, Multiethnic, Community-Based Cohort Study of Women and the Menopausal Transition , 2000 .

[28]  G. Grunwald,et al.  Differences in resting metabolic rate between white and African-American young adults. , 2002, Obesity research.

[29]  J. Sowers,et al.  Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. , 2002, Hypertension.

[30]  J. Morrow,et al.  Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension , 2003, Hypertension.

[31]  KristinaBjörklund,et al.  Isolated Ambulatory Hypertension Predicts Cardiovascular Morbidity in Elderly Men , 2003 .

[32]  S. Kumanyika.  Obesity in African Americans: biobehavioral consequences of culture. , 1998, Ethnicity & disease.

[33]  M A Waclawiw,et al.  Racial divergence in adiposity during adolescence: The NHLBI Growth and Health Study. , 2001, Pediatrics.

[34]  R. Palmer,et al.  Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. , 2003, American journal of hypertension.

[35]  D. Felson,et al.  A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. , 1993, Archives of internal medicine.

[36]  N. Bellamy.  Osteoarthritis clinical trials: candidate variables and clinimetric properties. , 1997, The Journal of rheumatology.

[37]  A. Whelton.  Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. , 1999, The American journal of medicine.

[38]  W. White.  Hypertension associated with therapies to treat arthritis and pain. , 2004, Hypertension.

[39]  J. Avorn,et al.  Relationship Between COX-2 Specific Inhibitors and Hypertension , 2004, Hypertension.

[40]  W. Murphy,et al.  The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. , 1990, Arthritis and rheumatism.

[41]  C. F. Richards.  Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta analysis , 1995 .

[42]  Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .

[43]  W. White,et al.  Effects of Celecoxib on Ambulatory Blood Pressure in Hypertensive Patients on ACE Inhibitors , 2002, Hypertension.

[44]  F. Buttgereit,et al.  [Selective COX-2 inhibition improves endothelial function in coronary artery disease]. , 2003, Zeitschrift fur Rheumatologie.

[45]  K. Markides,et al.  Behavioral risk factors related to chronic diseases in ethnic minorities. , 1995, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[46]  S. Grundy,et al.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1999, Circulation.

[47]  J E Keil,et al.  Socioeconomic factors and cardiovascular disease: a review of the literature. , 1993, Circulation.

[48]  J. Fiechtner,et al.  COX-2 Specific Inhibitors in the Management of Osteoarthritis of the Knee: A Placebo-Controlled, Randomized, Double-Blind Study , 2001, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[49]  Thomas J. Schnitzer,et al.  Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update , 2000 .

[50]  Peter W de Leeuw,et al.  Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. , 2003, The New England journal of medicine.

[51]  J. Palmer,et al.  Relative validity of food frequency questionnaire nutrient estimates in the Black Women's Health Study. , 2003, Annals of epidemiology.